{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?min-questionFirstAnswered.=2019-05-08T13%3A57%3A42.103Z&max-date=2019-05-14&creator.label=Biography+information+for+Sir+Mike+Penning", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?min-questionFirstAnswered.=2019-05-08T13%3A57%3A42.103Z&max-date=2019-05-14&creator.label=Biography+information+for+Sir+Mike+Penning", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?min-questionFirstAnswered.=2019-05-08T13%3A57%3A42.103Z&max-date=2019-05-14&_metadata=all&creator.label=Biography+information+for+Sir+Mike+Penning", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=0&min-questionFirstAnswered.=2019-05-08T13%3A57%3A42.103Z&max-date=2019-05-14&creator.label=Biography+information+for+Sir+Mike+Penning", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?min-questionFirstAnswered.=2019-05-08T13%3A57%3A42.103Z&max-date=2019-05-14&creator.label=Biography+information+for+Sir+Mike+Penning", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?min-questionFirstAnswered.=2019-05-08T13%3A57%3A42.103Z&max-date=2019-05-14&creator.label=Biography+information+for+Sir+Mike+Penning", "items" : [{"_about" : "http://data.parliament.uk/resources/1126459", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1126459/answer", "answerText" : {"_value" : "<p>It is right that these decisions are clinically led. As for any other medical treatment, if two clinicians are of the opinion that, on balance, it is not in the best interest of the patient to prescribe a cannabis-based product, then it will not be prescribed.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"}
        }
        , "answeringMemberConstituency" : {"_value" : "South Ribble"}
        , "answeringMemberPrinted" : {"_value" : "Seema Kennedy"}
        , "dateOfAnswer" : {"_value" : "2019-05-21", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2019-05-21T10:45:44.23Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2019-05-14", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Cannabis: Medical Treatments"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what the process will be for patients that are refused a prescription for medical cannabis oil by their second opinion; and will he make a statement.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1528", "label" : {"_value" : "Biography information for Sir Mike Penning"}
      }
      , "tablingMemberConstituency" : {"_value" : "Hemel Hempstead"}
      , "tablingMemberPrinted" : [{"_value" : "Sir Mike Penning"}
      ], "uin" : "254164"}
    , {"_about" : "http://data.parliament.uk/resources/1123519", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1123519/answer", "answerText" : {"_value" : "<p>NHS England has been asked to provide an interim report to the Secretary of State for Health and Social Care by the end of May 2019. The review will be clinically led by the NHS England and NHS Improvement Medical Director and Chief Pharmaceutical Officer, drawing on further specialist support as required.<\/p><p>NHS England will work with patient groups and the All Party Parliamentary Group on Medical Cannabis under Prescription to identify a sample of patients that have been seeking to access cannabis-based products for medicinal use through the National Health Service. Case reviews will involve interviews with relevant individuals who are involved in the decision to prescribe cannabis-based products for medicinal use, including patients, carers and relevant trust staff.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"}
        }
        , "answeringMemberConstituency" : {"_value" : "South Ribble"}
        , "answeringMemberPrinted" : {"_value" : "Seema Kennedy"}
        , "dateOfAnswer" : {"_value" : "2019-05-08", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : {"_value" : "248611"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2019-05-08T13:57:42.103Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2019-04-29", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Cannabis: Medical Treatments"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what the timeframe is for the process evaluation being undertaken by the NHS on prescribing cannabis-based products for medical use; and if he will he make a statement.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1528", "label" : {"_value" : "Biography information for Sir Mike Penning"}
      }
      , "tablingMemberConstituency" : {"_value" : "Hemel Hempstead"}
      , "tablingMemberPrinted" : [{"_value" : "Sir Mike Penning"}
      ], "uin" : "248610"}
    , {"_about" : "http://data.parliament.uk/resources/1123520", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1123520/answer", "answerText" : {"_value" : "<p>NHS England has been asked to provide an interim report to the Secretary of State for Health and Social Care by the end of May 2019. The review will be clinically led by the NHS England and NHS Improvement Medical Director and Chief Pharmaceutical Officer, drawing on further specialist support as required.<\/p><p>NHS England will work with patient groups and the All Party Parliamentary Group on Medical Cannabis under Prescription to identify a sample of patients that have been seeking to access cannabis-based products for medicinal use through the National Health Service. Case reviews will involve interviews with relevant individuals who are involved in the decision to prescribe cannabis-based products for medicinal use, including patients, carers and relevant trust staff.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"}
        }
        , "answeringMemberConstituency" : {"_value" : "South Ribble"}
        , "answeringMemberPrinted" : {"_value" : "Seema Kennedy"}
        , "dateOfAnswer" : {"_value" : "2019-05-08", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : {"_value" : "248610"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2019-05-08T13:57:42.167Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2019-04-29", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Cannabis: Medical Treatments"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, who he will be engaging with in the process evaluation on prescribing cannabis-based products for medical use.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1528", "label" : {"_value" : "Biography information for Sir Mike Penning"}
      }
      , "tablingMemberConstituency" : {"_value" : "Hemel Hempstead"}
      , "tablingMemberPrinted" : [{"_value" : "Sir Mike Penning"}
      ], "uin" : "248611"}
    , {"_about" : "http://data.parliament.uk/resources/1123521", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1123521/answer", "answerText" : {"_value" : "<p>To stimulate research proposals, the National Institute for Health Research (NIHR) has issued two calls for research into cannabis-based products for medicinal use and has taken steps to advertise the call to all manufacturers interested in supplying the United Kingdom market.<\/p><p>The NIHR also remain open to the submission of proposals outside of these specific calls. Proposals made to NIHR are assessed for scientific rigour, which will include the design of the trials, before funding is allocated to the applicants.<\/p><p>The process for selecting people for inclusion in any trials will be determined by the researchers and will be dependent on the study design used in the trial.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"}
        }
        , "answeringMemberConstituency" : {"_value" : "South Ribble"}
        , "answeringMemberPrinted" : {"_value" : "Seema Kennedy"}
        , "dateOfAnswer" : {"_value" : "2019-05-08", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2019-05-08T13:59:06.047Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2019-04-29", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Cannabis: Medical Treatments"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, how the National Institute for Health Research will identify patients with severe intractable epilepsy to use as a placebo in research into the safety and clinical efficacy and effectiveness of cannabis-based products for medical use in humans.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1528", "label" : {"_value" : "Biography information for Sir Mike Penning"}
      }
      , "tablingMemberConstituency" : {"_value" : "Hemel Hempstead"}
      , "tablingMemberPrinted" : [{"_value" : "Sir Mike Penning"}
      ], "uin" : "248612"}
    ], "itemsPerPage" : 10, "page" : 0, "startIndex" : 1, "totalResults" : 4, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}